The CFTC has accused New York company Gelfman Blueprint of operating a bitcoin-related Ponzi scheme, in the regulator’s first fraud-related action involving the cryptocurrency.
NYS Entity Status
NYS Filing Date
MARCH 18, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - NUKIS COMPANY CORP
Around the Web
- N.Y. Company Accused of Running Bitcoin Ponzi Scheme
Thursday Sep 21, 2017
- Billionaires, Bruised Egos, and the Death of a Grand Project
By CHARLES V. BAGLI and ROBIN POGREBIN - Sunday Sep 24, 2017
Barry Diller was about to win the battle for his $250 million arts pier, but then came the “petty questions” from his opponents and he decided to pull the plug.
- NY insurance company dragged into Wells Fargo scandal
By Kevin Dugan - Tuesday Aug 1, 2017
The New York insurance company that wrote policies for 800,000 questionable Wells Fargo auto loans has been dragged into the bank’s latest scandal. National General Insurance was named in a class-action lawsuit filed against the bank — for allegedly unduly profiting from $80 million in collateral protection insurance that the drivers didn’t need — and...
- Near The East River, Plans Emerge For NY’s Next Life Science Center
By Ben Fidler - Monday Aug 21, 2017
At a time when biotech incubators and shared spaces are beginning to multiply in Manhattan, work on what could rank among the city’s largest biotech centers—if it can all come together—is just getting underway. According to Paul Wexler, a longtime healthcare-focused real estate broker, construction should begin next year on what is being called the […]
- NY Times sees jump in digital subscription revenue
By Reuters - Thursday Jul 27, 2017
The New York Times said on Thursday its digital subscription revenue overtook print advertising revenue for the first time — a key milestone in the 166-year old publisher’s efforts to transform itself into a digital media powerhouse. The company’s shares rose as much as 7 percent to their highest since the 2008 financial crisis as...
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]